Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML.

Abstract:

:In ninety-three cases of newly diagnosed acute myeloid leukaemia (AML) we investigated the importance to short- and long term clinical outcome of the in vitro short term leukaemia cell survival as measured by a 4-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-assay. In 67 patients treated by intravenous remission induction therapy we found that patients who after the first induction cycle or after induction therapy overall achieved a complete remission (CR) had leukaemia cells with significantly lower in vitro cell survival ability than cells of non-responders (p = 0.02 and 0.06, respectively). These relations remained statistically significant in subsequent multivariate analyses. Likewise, a favourable effect of low in vitro leukaemia cell survival on overall survival of the patients was detected in the (largest) subgroup of adult patients treated uniformly by the same remission induction regimen as well as in all patients. However, in the 44 patients, who achieved CR, the in vitro leukaemia cell survival did not show significance to remission duration or time to first relapse. Furthermore, the leukaemia cell survival (MTT-assay) did not to correlate with the Bcl-2 expression level (quantitative flow cytometry) of the leukaemia cells (r = 0.18, n = 34, p = 0.32). In addition, in a cell line model employing the growth factor dependent MO7 human AML cell line, growth factor withdrawal was associated with rapid onset of cellular apoptosis as evaluated by morphology, occurrence of a subG1 peak in DNA histograms, and loss of cellular activity in the MTT-assay. In contrast, a more moderate decline in Bcl-2 expression and gradual loss of ability to exclude the trypan blue dye was seen in the leukaemia cells in response to growth factor withdrawal. We conclude, that the MTT-assay provides a simple and sensitive method for measuring in vitro cell survival. The differences in leukaemia cell survival seen in AML may well be clinically relevant and may help to provide a better understanding of clinical drug resistance.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Nørgaard JM,Jensen PD,Bendix K,Clausen N,Palshof T

doi

10.3109/10428199909167393

keywords:

subject

Has Abstract

pub_date

1999-01-01 00:00:00

pages

327-37

issue

3-4

eissn

1042-8194

issn

1029-2403

journal_volume

32

pub_type

临床试验,杂志文章
  • Changing landscape of frontline therapy in chronic lymphocytic leukemia.

    abstract::The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-ce...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1688321

    authors: Bhat SA,Woyach JA

    更新日期:2020-03-01 00:00:00

  • Neutropenia and leukemia development: genetic risk factors and prognosis.

    abstract::Neutropenia is known as a clinical consequence in various genetic disorders and other neutropenia-inducing mutations (NIM) nonmalignant diseases. Leukemia development is now a major concern about the mortality of patients with congenital neutropenia. We searched the PubMed database and Google Scholar engine using Engl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2019.1630622

    authors: Shahrabi S,Maleknia M,Tavakolifar Y,D Zayeri Z,Saki N

    更新日期:2019-12-01 00:00:00

  • 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma.

    abstract::We describe a patient with unusually indolent hepatosplenic gammadelta T cell lymphoma characterised by severe lassitude and high fever. No significant responses were obtained to a range of chemotherapeutic and biological agents. 2'-deoxycoformycin (dCF), however, produced a dramatic and sustained clinical and histolo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109099342

    authors: Grigg AP

    更新日期:2001-08-01 00:00:00

  • Lymphomatous proptosis as a novel feature of mantle cell lymphoma.

    abstract::We describe eight cases of acute proptosis due to mantle cell lymphoma (MCL), among 26 consecutive MCL cases. The median time of onset was 29 months (range 0-102) from diagnosis. Two cases presented initially with orbital masses while five as sudden disease progression after multiple courses of chemotherapy. In each c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500301058

    authors: Hon C,Chan RT,Ma ES,Shek TW,Yau K,Au WY

    更新日期:2006-01-01 00:00:00

  • Report of novel chromosomal abnormalities in a series of 130 chronic lymphocytic leukemia patients studied by classic cytogenetic analysis.

    abstract::One-hundred-and-thirty typical, unselected CLL cases were studied by conventional cytogenetic analysis. Seventy-three patients (56.2%) had normal karyotype ('normal sub-group'), while 57/130 patients (43.8%) had abnormal karyotype. Twenty-two of 57 patients (38.6%) carried more than one abnormality. Six novel chromoso...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600881447

    authors: Athanasiadou A,Stamatopoulos K,Tsezou A,Vadikolia C,Asteriou O,Fassas A,Anagnostopoulos A

    更新日期:2006-10-01 00:00:00

  • Chromosomal analysis of purified B-chronic lymphocytic leukemia lymphocyte cultures: comparison with whole blood cultures and in situ hybridization.

    abstract::Chromosomal analysis of stimulated whole blood cells and purified B lymphocytes was performed in 13 stage A(0) and 1 stage C(IV) chronic lymphocytic leukemia (B-CLL) patients. Abnormal clones were found in 6 cases in purified B lymphocytes cultures and in a single one in whole blood cultures. In situ hybridization wit...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309067929

    authors: Brizard A,Brizard F,Dreyfus B,Morel F,Lecron JC,Tanzer J,Preud'Homme JL

    更新日期:1993-11-01 00:00:00

  • The role of aberrant transcription factor in the progression of chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological and clinical features. The Philadelphia (Ph) chromosome and BCR/ABL fusion gene is the major cytogenetic and molecular marker of CML chronic phase. However, the molecular mechanisms of disease progression are not well known. R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802163305

    authors: Zhang S

    更新日期:2008-08-01 00:00:00

  • Three cases of primary cutaneous lymphoblastic lymphoma: microarray-based comparative genomic hybridization and gene expression profiling studies with review of literature.

    abstract::Lymphoblastic lymphoma (LBL) is a neoplasm of precursor B- or T-lymphocytes, and primary skin involvement is uncommon. The aim of the study was to review all reported primary cutaneous (PC)-LBLs and to examine three new cases to better characterize this neoplasm. Two of our patients showed a pre-B phenotype (PC-B-LBL)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.618233

    authors: Vezzoli P,Novara F,Fanoni D,Gambini D,Balice Y,Venegoni L,Paulli M,Crosti C,Berti E

    更新日期:2012-10-01 00:00:00

  • Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.

    abstract::We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy. Patients receiving DCAG had a similar overall response rate (ORR) (p = ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1443328

    authors: Huang J,Hong M,Zhu Y,Zhao H,Zhang X,Wu Y,Lian Y,Zhao X,Li J,Qian S

    更新日期:2018-11-01 00:00:00

  • CD105 (endoglin) expression on hematopoietic stem/progenitor cells.

    abstract::Endoglin (CD105) is a component of the transforming growth factor-beta (TGF-beta) receptor (TGF-betaR) complex. Together with betaglycan, CD105 is considered as a TGF-betaR accessory molecule (also called TGF-betaRIII), but its functions in the receptor-ligand interactions are still poorly understood. A small subset o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109097744

    authors: Pierelli L,Bonanno G,Rutella S,Marone M,Scambia G,Leone G

    更新日期:2001-11-01 00:00:00

  • Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma.

    abstract::Sarcopenia is associated with treatment-related complications and shorter overall survival in patients with cancer. Psoas area indices were calculated for 121 patients with lymphoma who underwent autologous transplant. Controlling for age, body mass index, comorbidities and performance status for the 73 men included, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1014359

    authors: Caram MV,Bellile EL,Englesbe MJ,Terjimanian M,Wang SC,Griggs JJ,Couriel D

    更新日期:2015-01-01 00:00:00

  • Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.

    abstract::The prognostic significance of immunophenotype and other features including sex, age, anaemia, WBC, FAB type, and PAS staining were analysed in a group of 389 children newly diagnosed as acute lymphoblastic leukemia (ALL) and treated according to the BFM 1981/1983 protocol. The CR rate was higher (82-94%) in immunophe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209053627

    authors: Holowiecki J,Koehler M,Zintl Z,Kardos G,Lutz D,Krzemien S,Rewesz T,Brugiatelli M,Callea V,Kachel L

    更新日期:1992-06-01 00:00:00

  • Enhanced histone deacetylase enzyme activity in primary myelofibrosis.

    abstract::We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p<0.05). Sixteen patients...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802527699

    authors: Wang JC,Chen C,Dumlao T,Naik S,Chang T,Xiao YY,Sominsky I,Burton J

    更新日期:2008-12-01 00:00:00

  • An unusual case of composite lymphoma involving chronic lymphocytic leukemia follicular lymphoma and Hodgkin disease.

    abstract::Composite lymphomas constitute the presence of two different types of non-Hodgkin lymphoma or Hodgkin and non-Hodgkin lymphoma at the same anatomic site. We report an unusual case of a 73-year-old woman who initially presented with a composite lymphoma of chronic lymphocytic leukemia (CLL) and follicular lymphoma. Aft...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819032000159870

    authors: Copur MS,Ledakis P,Novinski D,Fu K,Hutchins M,Frankforter S,Mleczko K,Sanger WG,Chan WC

    更新日期:2004-05-01 00:00:00

  • Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.

    abstract::Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509054750

    authors: Vacca A,Ribatti D,Roncali L,Dammacco F

    更新日期:1995-12-01 00:00:00

  • Hyperthyroidism six years post-BMT for acute myeloblastic leukemia in a patient on long-term lithium therapy for bipolar affective disorder.

    abstract::Lithium is commonly used to treat bipolar affective disorder. It is well known to adversely affect thyroid function, most commonly causing hypothyroidism. Hyperthyroidism is a rare complication. Similarly, total body irradiation (TBI) associated with BMT is well known to affect thyroid function frequently causing hypo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001617286

    authors: Law A,Rifkind J,Rosen F,Lipton JH

    更新日期:2004-04-01 00:00:00

  • Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

    abstract::Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1554862

    authors: Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

    更新日期:2019-07-01 00:00:00

  • The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.

    abstract::Lymphoid recovery following myeloablative stem cell transplantation (SCT) displays a logistic pattern of exponential growth followed by a plateau. Within this logistic framework, lymphoid recovery is characterized by the parameters R (slope of ascent), a (time of maximal rate of ascent) and K (plateau), the 'steady-st...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1452216

    authors: Kobulnicky DJ,Sabo RT,Sharma S,Shubar Ali AS,Kobulnicky KM,Roberts CH,Clark WB,Chung HM,McCarty JM,Toor AA

    更新日期:2018-12-01 00:00:00

  • Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures.

    abstract::EBER in situ hybridization (EBER) and LMP-1 immunohistochemistry (LMP-1) are widely used for identifying Epstein-Barr virus (EBV) within tumor cells of Hodgkin lymphoma (HL), but measurement error has never been formally evaluated. To determine assay reliability, 40 HL tumors with known EBV status were stained for bot...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819032000141310

    authors: Glaser SL,Gulley ML,Borowitz MJ,Craig FE,Mann RB,Stewart SL,Shema SJ,Ambinder RF

    更新日期:2004-03-01 00:00:00

  • Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

    abstract::There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with relapsed or refractory...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.555892

    authors: Buckstein R,Kuruvilla J,Chua N,Lee C,Macdonald DA,Al-Tourah AJ,Foo AH,Walsh W,Ivy SP,Crump M,Eisenhauer EA

    更新日期:2011-05-01 00:00:00

  • Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

    abstract::Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognostic factors for survival in different malignancies. This study determined the association of LMM and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measurement of muscle was performed in 164 DLBCL pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1737686

    authors: Rier HN,Kharagjitsing H,van Rosmalen J,van Vugt J,Westerweel PE,de Jongh E,Kock M,Levin MD

    更新日期:2020-07-01 00:00:00

  • Hematological toxicities associated with amphotericin B formulations.

    abstract::Even though amphotericin B is associated with considerable hematological toxicity, this subject has been poorly studied. This retrospective cohort study assessed the incidence and predictors of hematological toxicity in patients treated with different amphotericin B formulations: amphotericin B deoxycholate (d-AmB), l...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1010080

    authors: Falci DR,da Rosa FB,Pasqualotto AC

    更新日期:2015-01-01 00:00:00

  • Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

    abstract::The aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with vi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.769219

    authors: Honeychurch J,Melis MH,Dovedi SJ,Mu L,Illidge TM

    更新日期:2013-09-01 00:00:00

  • Peripheral blood lymphocyte subsets of newly diagnosed DLBCL patients and their dynamic changes with rituximab based immunochemotherapy.

    abstract::The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L, p = 0.003), mostly...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1617861

    authors: Yang Z,Yu W,Wang S,Zhou X,Liu S,Ma S

    更新日期:2019-12-01 00:00:00

  • Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

    abstract::Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1361022

    authors: Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

    更新日期:2018-04-01 00:00:00

  • Mechanisms of protection of hematopoietic stem cells from irradiation.

    abstract::Current therapies for the treatment of malignancies are associated with significant limitations to the hematopoietic system since chemotherapy and radiation therapy do not discriminate between normal and malignant cells. Since bone marrow depression occurs at low to midlethal doses of irradiation, approaches to improv...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409051648

    authors: Zucali JR

    更新日期:1994-03-01 00:00:00

  • Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma.

    abstract::Current chemoimmunotherapy is unable to cure up to 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). Targeting the mechanisms by which DLBCL evades apoptosis is crucial to overcoming treatment failure in this heterogeneous disease as both current and novel treatments depend on the apoptosis of mali...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1795156

    authors: Gifford G,Stevenson W,Best G

    更新日期:2020-12-01 00:00:00

  • Treatment of young relapsed Hodgkin's disease patients with high-dose chemotherapy followed by peripheral blood stem cell transplantation.

    abstract::Four patients less than 20 years of age with Hodgkin's disease, who had developed either second or third relapse, were treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT). Peripheral blood stem cells (PBSC) were collected after the administration of high-dose cytosine ara...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509059652

    authors: Matsuzaki A,Okamura J,Nagatoshi Y,Kai T,Ohga S,Gondo H,Inaba S,Ueda K

    更新日期:1995-08-01 00:00:00

  • Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.

    abstract::It is now known that syngeneic transplantation, T lymphocyte depletion and absence of graft-versus-host disease all increase the risk of relapse following allogeneic transplantation for the myeloid leukemias, both acute and chronic. Leukemia-specific immune responses appear to play a major role in the therapy of the m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309067922

    authors: Rowe JM,Nilsson BI,Simonsson B

    更新日期:1993-11-01 00:00:00

  • Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?

    abstract::T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoproliferative disorder with distinctive clinical and laboratory features. It is often resistant to conventional chemotherapy, but complete or partial responses have been documented with the use of purine analogues. We report on two cases of T-PLL with a slightly d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000040035

    authors: Delgado J,Bustos JG,Jimenez MC,Quevedo E,Hernandez-Navarro F

    更新日期:2002-12-01 00:00:00